VUG - Vanguard Growth ETF

NYSEArca - Nasdaq Real Time Price. Currency in USD
134.860
-0.350 (-0.259%)
As of 3:22PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close135.210
Open134.650
Bid134.830 x 500
Ask134.840 x 800
Day's Range134.160 - 134.919
52 Week Range106.870 - 135.500
Volume330,231
Avg. Volume564,892
Net Assets68.45B
NAV132.77
PE Ratio (TTM)66.43
Yield1.25%
YTD Return20.14%
Beta (3y)1.05
Expense Ratio (net)0.06%
Inception Date2004-01-26
Trade prices are not sourced from all markets
  • Vanguard, genocide, and the $18 million campaign to get you to vote
    Yahoo Finance Video5 hours ago

    Vanguard, genocide, and the $18 million campaign to get you to vote

    An activist group at Vanguard is asking shareholders to vote in favor of a proposal that would not allow the mutual fund giant to invest in companies that contribute to genocide or crimes against humanity. Yahoo Finance’s Alexis Christoforous, Ethan Wolff-Mann and Dan Roberts talk about why Vanguard is recommending its clients to vote against the proposal.

  • Vanguard, genocide, and the $18 million campaign to get you to vote
    Yahoo Financeyesterday

    Vanguard, genocide, and the $18 million campaign to get you to vote

    Why is Vanguard voting against a shareholder measure on its proxy ballot that moves to stop investing in companies that "substantially contribute" to genocide?

  • 3 Top Ranked Large-Cap Growth ETFs for Your Portfolio
    Zacks6 days ago

    3 Top Ranked Large-Cap Growth ETFs for Your Portfolio

    Large-cap growth ETFs are garnering a lot of attention, owing to global economic growth.

  • Benzinga21 days ago

    A Solid Start For This New ETF

    This has been another year of brisk new product launches from the exchange-traded funds industry as hundreds of new funds have come to market. As is often the case, some new ETFs take awhile to attract ...

  • Market Realistlast month

    Could Mylan’s Biosimilar Portfolio Be a Long-Term Growth Driver?

    According to a Deloitte report, the biosimilars market is expected to grow to a market value of more than $445.0 billion by the end of 2019.

  • Market Realistlast month

    BD Stock Fell 2.7% on September 13: Should Investors Worry?

    Becton, Dickinson and Company (BDX) closed at $196.62 on September 13, 2017.

  • Benzingalast month

    Going With Growth ETFs

    This year, the growth factor resumed its outperformance of the value factor, benefiting a host of exchange traded funds along the way. Investors can easily access growth stocks via ETFs, whether be by ...

  • ETF Trendslast month

    10 Super-Cheap Vanguard ETFs for Investors

    ETF adoption has rapidly accelerated in recent years, with many investors steering to cheap ETFs to potentially bolster long-term investment returns. There are 2,040 U.S.-listed ETFs on the market with ...

  • Barrons.comlast month

    ETF Price War Is Heating Up; That's Bad News for Some Fund Firms

    Goldman Sachs Asset Management is ramping up a price war with the pending launch of a new "smart-beta" exchange-traded fund with an expense ratio as low as 0.09% (or 9 basis points) -- a level even lower than some passive index funds, says Moody's Investors Service. Analyst Stephen Tu writes: GSAM’s move expands the ETF price war beyond plain vanilla ETFs into smart-beta ETFs, implying that the industry’s higher pricing assumptions for smart-beta products will not hold.

  • Market Realistlast month

    Boston Scientific’s Updated 2017 Guidance

    Boston Scientific (BSX) expects to register 2017 revenues of $8.9 billion–$9.0 billion compared to its previous guidance of $8.8 billion–$8.9 billion.

  • Market Realist2 months ago

    How Are Orkambi and Kalydeco Positioned after 2Q17?

    In 2Q17, Vertex Pharmaceuticals’ (VRTX) Orkambi generated revenues of around $324 million, which reflected a whopping ~32% growth on a year-over-year (or YoY) basis and ~10% growth on a quarter-over-quarter ...